GSK delivered the kind of quarter most boards would welcome, and still watched its share price fall. Third-quarter results published on 28 October showed revenue up 5% to £8.9 billion and core operating profit up 5% to £3.1 billion, both ahead of analyst forecasts. Full-year guidance of 3% to 5% revenue growth was reaffirmed.
The market looked past all of that to one line. Vaccine sales fell 2% to £2.6 billion, below expectations, and GSK shares dropped by between 5% and 7% in London trading as investors reacted.
Where the Weakness Sits
Two products did most of the damage. Shingrix, GSK’s shingles vaccine and one of its largest products, fell 5% to £0.8 billion. GSK said the decline came mainly from lower sales outside the US, primarily China, partly offset by higher US pricing and stock building during the quarter. Arexvy, its vaccine for respiratory syncytial virus (RSV) in older adults, fell 24% to around £0.2 billion as demand faded after a strong launch.
There was good news inside the division. Meningitis vaccines grew 12% to £0.6 billion, and chief executive Luke Miels pointed to rising US shingles vaccination rates, now at 46%. GSK has also moved an mRNA seasonal flu vaccine into Phase 3 trials.
The growth story now belongs to specialty medicines, which grew 15% and include treatments for HIV, cancer and respiratory disease. GSK has secured three new US specialty approvals in recent months and says it remains on track for its 2031 target of more than £40 billion in annual sales.
Why a Good Quarter Was Not Enough
The reaction says more about investor psychology than about GSK’s overall health. Vaccines were once the steady, defensible core of the business. Since the pandemic, vaccine demand across the industry has become less predictable, shaped by public sentiment, government purchasing decisions and changing recommendations. When the most visible growth engine stalls, investors start to question the long-range targets that depend on it, however well the rest of the business performs.
Rivals have faced the same pressure. RSV vaccine sales have disappointed across the sector after early uptake, and makers of COVID-19 vaccines have had to reset expectations repeatedly. GSK’s numbers show that a broad portfolio cushions the blow to revenue but not to valuation.
The BusinessIQˣ View: Lessons for Leadership Teams
The impact. For healthcare buyers, little changes in the short term: supply of GSK’s vaccines and medicines is unaffected. The wider lesson is for any company whose equity story rests on a single flagship product or service. Markets price the direction of your best-known business line, and a slowdown there can outweigh solid results everywhere else. Pension funds and investors with large UK pharmaceutical holdings should also note how quickly sentiment can turn on one product category.
What to do now:
1. Identify the one business line investors, lenders or buyers watch most closely in your company, and track its leading indicators monthly, not quarterly.
2. Prepare the explanation before you need it. If that line slows, have the data on why, how long it will last and what is replacing the growth ready for your board and investors.
3. Check how concentrated your revenue really is. If one product or customer group provides more than a third of growth, set a target and a timeline for reducing that dependence.
4. Watch demand that depends on public policy. Where sales rely on government recommendations, reimbursement or purchasing, build scenarios for a policy change and review them with your finance team twice a year.
5. When you report results, lead with the forward pipeline. GSK’s specialty growth and 2031 target were strong, yet the headlines were about vaccines because that was where the surprise was.
GSK’s quarter was better than its share price suggests. That gap between performance and perception is exactly what leadership teams need to plan for.
